Contract research organisation Sinclair Research on Thursday announced an agreement to acquire the assets of the GLP safety pharmacology business unit of CorDynamics, a provider of cardiovascular toxicology and safety pharmacology contract research services.
The addition of CorDynamics' GLP safety pharmacology programme to Sinclair's growing nonclinical toxicology services is a good strategic fit and enables Sinclair to support critical IND-enabling programmes at a single research site, according to the company's vice president of commercial operations Andy Brown.
"Sinclair Research will be able to provide in vivo safety pharmacology studies, standalone or as part of an IND-enabling package, to help pharmaceutical developers assess the potential for adverse effects prior to first-in-human trials," he added.
"We're excited to offer non-GLP screening studies and GLP core battery studies in the future."
In addition to being able to support safety pharmacology core battery assessments of cardiovascular, respiratory and central nervous systems, Sinclair's strategic partnership with CorDynamics brings many years of expertise in studying primary and secondary pharmacodynamic effects in vital organ systems, for a wide range of test materials, in multiple preclinical species, the company said.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study